Scotiabank raised the firm’s price target on BioMarin (BMRN) to $80 from $78 and keeps a Sector Perform rating on the shares. The firm is raising its price target on the stock following a Q4 Voxzogo beat and bullish 2025 revenue outlook, the analyst tells investors. Scotiabank, however, maintains its rating due to concerns about the potential competitive threats to the Voxzogo franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target raised to $113 from $109 at UBS
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Growth Prospects Warrant Buy Rating
- BioMarin price target raised to $103 from $99 at BofA
- Strong Financial Performance and Positive Outlook for BioMarin Pharmaceutical
- Strong Financial Performance and Strategic Growth Drive Buy Rating for BioMarin Pharmaceutical